Article info
PDFAdverse drug reactions
Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19
- Correspondence to Dr Robert Likic, Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; robert.likic{at}mef.hr
Citation
Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19
Publication history
- Received February 3, 2021
- Revised March 24, 2021
- Accepted March 25, 2021
- First published April 20, 2021.
Online issue publication
June 22, 2022
Article Versions
- Previous version (20 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage